Search Results
Jan 12, 2026, 07:30 ET AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors. PD-1/VEGF-targeted bispecific antibodies represent
More news about: AbbVie
Jan 12, 2026, 06:45 ET Canada Nickel Announces 46% Increase in Measured & Indicated Resource at Reid Nickel Sulphide Project
S (%) Pd (g/t) Pt (g/t)
More news about: Canada Nickel Company Inc.
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab.The multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893), known as the TWINPEAK study, is currently
More news about: Phanes Therapeutics, Inc.
Jan 08, 2026, 12:11 ET ELEPHAS BIOSCIENCES STRENGTHENS SCIENTIFIC AND CLINICAL LEADERSHIP AS COMPANY ADVANCES TOWARD COMMERCIAL AVAILABILITY OF ITS LIVE-TUMOR IMMUNOLOGY PLATFORM
director and scientific advisor. During his tenure at Bristol Myers Squibb, he led immuno-oncology strategy and clinical development for CTLA-4 (Yervoy) and PD-1 (Opdivo) from preclinical stages through commercialization. With 25 years of global development, medical affairs, and commercialization leadership
More news about: Elephas
Jan 08, 2026, 10:48 ET Global Times: Thought lights path toward the new: Dialogue with Yang Peng, Party secretary and chairman of Chuyuan Group
Era, People's Daily reporters (PD) conducted an interview with Yang Peng (Yang), Party secretary and chairman of Chuyuan Group, the "Young Yang" featured in the article on Monday. 'With clear thought, obstacles yield'PD: In 2016, Chuyuan received an "astronomical
More news about: Global Times
Jan 08, 2026, 09:00 ET Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
update on the PD-L1 protein degrader program; the interpretation, durability, and potential significance of clinical and preclinical results; the continued development, regulatory pathway, and the potential therapeutic benefits of the Company's product candidates, including paxalisib and its PD-L1 protein
More news about: Kazia Therapeutics Limited
Jan 08, 2026, 08:50 ET Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
ASPIRO Phase 1/2a trial of ANPD001, a personalized dopaminergic neuronal precursor cell (DANPC) therapy for moderate to advanced Parkinson's disease (PD). The company also announced the completion of construction of its current GMP manufacturing build‑out in San Diego.
More news about: Aspen Neuroscience, Inc.
Jan 08, 2026, 08:00 ET What to Do When Students Don't Learn: Start by Attending Solution Tree's 2026 Summit on RTI at Work™
more than 12,000 days of on-site PD delivered annually, Solution Tree helps teachers and administrators address their most pressing challenges. The organization offers a catalog of more than 600 titles, hundreds of videos and online courses, and is the creator of Global PD Teams and Avanti—online learning
More news about: Solution Tree
Jan 08, 2026, 07:30 ET KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer
metastatic microsatellite stable colorectal cancer (MSS-CRC). DSP107 was evaluated in combination with atezolizumab (Tecentriq®), an anti–PD-L1 therapy. The combination demonstrated favorable safety, clinical evidence of antitumor activity, and extended survival, including in patients with
More news about: KAHR Medical
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
clinical development. STC-15 is currently being evaluated in a Phase 1b/2 study in combination with LOQTORZI®, (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, in patients with NSCLC, HNSCC, melanoma, and endometrial cancer. Further information is available at
More news about: STORM Therapeutics
Jan 07, 2026, 07:00 ET AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study evaluated safety, tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and in patients with mutations in the SOD1 gene.About AL-S Pharma
More news about: AL-S Pharma AG
Jan 06, 2026, 21:50 ET Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final analysis data from the AK112-301/HARMONi-A study, which demonstrated statistically
More news about: Akeso, Inc.
Jan 06, 2026, 17:10 ET Music Buzzz Podcast Kicks Off Season 6 with Legendary Guitarist and All-Star Guest Lineup for 2026
https://www.audible.com/pd/Music-Buzzz-Podcast-Podcast/B08JJN56YQiHeart:
More news about: ELEVATE Entertainment & Event Support Services
Jan 06, 2026, 13:32 ET Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Consistent PFS benefit across PD-L1 status, geographic region, andECOG performance statusConsistent PFSand OS benefit across PD-L1 status, geographic region,
More news about: Jazz Pharmaceuticals plc
Jan 06, 2026, 10:00 ET 綠聯在2026年CES上推出由AI NAS領銜的新智能生態系統
300W桌面充電器：為每台設備提供更智能的電力供應綠聯在CES展會上推出的壓軸產品是Nexode Pro 300W氮化鎵桌面充電器，這是一款專為多設備家庭和工作空間設計的八口桌面充電站。它可以智能地分配電力至所連接的筆記本電腦、平板電腦和手機，確保每台設備都能獲得最佳充電速度與保護。其核心功能包括：三個140W PD 3.1接口，可以為筆記本電腦快速充電；一個專為遊戲本和工作站設計的240W DC（直流電）接口；以及一塊3英吋TFT（薄膜晶體管）顯示屏，可以實時顯示充電狀態。用戶還能從五種智能充電模式中選擇，通過綠聯App監控和調節設置，並依托Thermal Guard熱防護技術實現安全大功率充電。
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET Aurzen Elevates Portable Entertainment with New Innovations at CES 2026
10W Dolby Audio speakers. Despite its compact size, it delivers an immersive, studio-quality audio experience. BOOM air supports USB-C power and 65W PD power banks, making it well suited for on-the-go and outdoor use.Aurzen has expanded its smart projector ecosystem beyond its previous Google
More news about: Aurzen Official
Jan 06, 2026, 10:00 ET 유그린, CES 2026서 AI NAS 앞세운 차세대 스마트 생태계 공개
Desktop Charger다. 8개의 포트를 갖춘 이 제품은 여러 기기를 동시에 사용하는 가정이나 업무 공간에 최적화됐다. 연결된 노트북, 태블릿, 스마트폰에 전력을 지능적으로 분배해 각 기기에 맞는 최적의 속도로 안전하게 충전한다. 노트북 고속 충전을 위한 140W PD 3.1 포트 3개, 게이밍 노트북이나 워크스테이션용 240W DC 포트 1개를 탑재했으며, 3인치 박막 트랜지스터(TFT) 디스플레이로 충전 상태를 실시간 확인할 수 있다. 5가지 스마트 충전 모드를 선택할 수 있고 유그린 앱(UGREEN App)으로 설정 제어가 가능하며,
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN stellt auf der CES 2026 ein neues intelligentes Ökosystem vor, das von AI NAS geleitet wird
Telefone und sorgt so dafür, dass jedes Gerät die optimale Geschwindigkeit und den optimalen Schutz erhält. Zu den wichtigsten Merkmalen gehören drei 140-W-PD-3.1-Anschlüsse für schnelles Laden von Laptops, ein dedizierter 240-W-DC-Anschluss für Gaming-Laptops und Workstations sowie ein 3-Zoll-TFT-Display,
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN Debuts New Smart Ecosystem at CES 2026, Led by AI NAS
distributes power across connected laptops, tablets, and phones, ensuring each receives optimal speed and protection. Key features include three 140W PD 3.1 ports for fast laptop charging, a dedicated 240W DC port for gaming laptops and workstations, and a 3-inch TFT display that shows real-time charging
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN Debuts New Smart Ecosystem at CES 2026, Led by AI NAS
distributes power across connected laptops, tablets, and phones, ensuring each receives optimal speed and protection. Key features include three 140W PD 3.1 ports for fast laptop charging, a dedicated 240W DC port for gaming laptops and workstations, and a 3-inch TFT display that shows real-time charging
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN presenta un nuevo ecosistema inteligente en CES 2026, liderado por IA NAS
teléfonos conectados, garantizando que cada uno reciba una velocidad y protección óptimas. Entre sus características principales se incluyen tres puertos PD 3.1 de 140 W para una carga rápida de portátiles, un puerto de CC dedicado de 240 W para portátiles y estaciones de trabajo para juegos, y una pantalla
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN revela novo ecossistema inteligente na CES 2026, com foco em soluções NAS com inteligência artificial
distribuição de energia, assegurando que laptops, tablets e smartphones recebam potência ideal com segurança e eficiência. Entre os destaques estão três portas PD 3.1 de 140 W para carregamento rápido de laptops, uma porta DC dedicada de 240 W para notebooks gamers e estações de trabalho, além de uma tela TFT de
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN presenta un nuevo ecosistema inteligente en CES 2026, dirigido por AI NAS
y teléfonos conectados, lo que garantiza que cada dispositivo reciba velocidad y protección óptimas. Las características clave incluyen tres puertos PD 3.1 de 140 W para carga rápida de computadora portátil, un puerto DC de 240 W ewspecial para computadoras portátiles, estaciones de trabajo para juegos
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 10:00 ET UGREEN présente son nouvel écosystème intelligent et sa série phare NAS optimisée par l'IA au CES 2026
et les téléphones connectés, garantissant à chacun une vitesse et une protection optimales. Les principales caractéristiques comprennent trois ports PD 3.1 de 140 W pour une charge rapide des ordinateurs portables, un port DC de 240 W dédié aux ordinateurs portables de jeu et aux stations de travail,
More news about: UGREEN GROUP LIMITED
Jan 06, 2026, 09:30 ET Lung Cancer Research Foundation Announces Additional 2025 Scientific Research Grant Awards
benefit a greater number of patients. This project seeks to understand mechanisms underlying the failure of some tumors to respond to combined KRAS and PD-L1/PD-1 inhibition. By identifying the transcriptional regulators of chemokines that recruit T cells and turn immune "cold" tumors "hot", this work will
More news about: Lung Cancer Research Foundation